, Volume 37, Issue 2, pp 185–192 | Cite as

Farnesol and geranylgeraniol: Prevention and reversion of lovastatin-induced effects in NIH3T3 cells

  • Susan E. Ownby
  • Raymond J. HohlEmail author


Mevalonic acid-derived intermediates in the cholesterol biosynthetic pathway have been recognized as being critical to the isoprenylation of a variety of growth-regulating proteins, including those of the RAS superfamily. Treatment of cells with lovastatin, a hydroxymethylglutaryl coenyme A (HMG-CoA) reductase inhibitor, depletes cells of mevalonic acid and thus blocks the isoprenylation of proteins in the RAS superfamily. In NIH3T3 cells pretreated with lovastatin, subsequent addition of farnesol (FOH), but not geranylgeraniol (GGOH), reverses lovastatin’s block of RAS isoprenylation. Neither FOH nor GGOH prevents lovastatin-induced inhibition of RAS isoprenylation when added to cells concurrently with lovastatin. In intact cells, 167 μM FOH and 125 μM GGOH decrease incorporation of [14C]acetate into cholesterol by approximately 50 and 75%, respectively. Results suggest that the radiolabel from either [3H]FOH or [3H]GGOH is incorporated into cholesterol. Co-treatment of cells with lovastatin or mevalonic acid did not significantly alter [3H]FOH or [3H]GGOH incorporation into cholesterol. Lovastatin induces cell rounding; GGOH, but not FOH, both prevents and reverses lovastatin-induced cell rounding. These results provide additional evidence for the existence of a novel “isoprenoid shunt” that differentially utilizes FOH and GGOH as metabolic precursors for isoprenoids that have been depleted by lovastatin treatment.


Lovastatin NIH3T3 Cell Farnesol Mevalonic Acid Bovine Calf Serum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



controlled processes serum replacements-1






hydroxymethylglutaryl coenzyme A


immunoglobulin G






relative mobility




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hancock, J.F., Magee, A.I., Childs, J.E., and Marshall, C.J. (1989) All ras Proteins Are Polyisoprenylated but Only Some Are Palmitoylated, Cell 57, 1167–1177.PubMedCrossRefGoogle Scholar
  2. 2.
    Schafer, W.R., Kim, R., Sterne, R., Thorner, J., Kim, S.H., and Rine, J. (1989) Genetic and Pharmacological Suppression of Oncogenic Mutations in RAS Genes of Yeast and Humans, Science 245, 379–385.PubMedCrossRefGoogle Scholar
  3. 3.
    Endo, A., Kuroda, M., and Tsujita, Y. (1976) ML-236A, ML-236B, and ML-236C, New Inhibitors of Cholesterogenesis Produced by Penicillium citrinium J. Antibiotics 29, 1346–1348.Google Scholar
  4. 4.
    Schmidt, R.A., Schneider, C.J., and Glomset, J.A. (1984) Evidence for Post-translational Incorporation of a Product of Mevalonic Acid into Swiss 3T3 Cell Proteins, J. Biol. Chem. 259, 10175–10180.PubMedGoogle Scholar
  5. 5.
    Schafer, W.R., and Rine, J. (1992) Protein Prenylation: Genes, Enzymes Targets and Functions, Annu. Rev. Genet. 30, 209–237.CrossRefGoogle Scholar
  6. 6.
    Rowinsky, E.K., Windle, J.J., and Van Hoff, D.D. (1999) Ras Protein Farnesyltransferase: A Strategic Target for the Anticancer Therapeutic Development, J. Clin. Oncol. 17, 3631–3652.PubMedGoogle Scholar
  7. 7.
    Lebowitz, P.F., Casey, P.J., Prendergas, G.C., and Thissen, J.A. (1997) Farnesyltransferase Inhibitors Alter the Prenylation and Growth-Stimulating Function of RhoB, J. Biol. Chem. 272, 15591–15594.PubMedCrossRefGoogle Scholar
  8. 8.
    Rowell, C.A., Kowalczyk, J.J., Lewis, M.D., and Garcia, A.M. (1997) Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in vivo, J. Biol. Chem. 272, 14093–14097.PubMedCrossRefGoogle Scholar
  9. 9.
    Crick, D.C., Waechter, C.J., and Andres, D.A. (1994) Utilization of Geranylgeraniol for Protein Isoprenylation in C6 Glial Cells, Biochem. Biophys. Res. Commun. 205, 955–961.PubMedCrossRefGoogle Scholar
  10. 10.
    Crick, D.C., Andres, D.A., and Waechter, C.J. (1995) Farnesol Is Utilized for Protein Isoprenylation and the Biosynthesis of Cholesterol in Mammalian Cells, Biochem. Biophys. Res. Commun. 211, 590–599.PubMedCrossRefGoogle Scholar
  11. 11.
    Crick, D.C., Andres, D.A., and Waechter, C.J. (1997) Geranylgeraniol Promotes Entry of UT-2 Cells into the Cell Cycle in the Absence of Mevalonate, Exp. Cell Res. 231, 302–307.PubMedCrossRefGoogle Scholar
  12. 12.
    Crick, D.C., Andres, D.A., and Waechter, C.J. (1998) Geranylgeraniol Overcomes the Block of Cell Proliferation by Lovastatin in C6 Glioma Cells, J. Neurochem. 70, 2397–2405.PubMedCrossRefGoogle Scholar
  13. 13.
    Andres, D.A., Crick, D.C., Finlin, B.S., and Waechter, C.J. (1999) Rapid Identification of Cysteine-Linked Isoprenyl Groups by Metabolic Labeling with [3H]Farnesol and [3H]Geranylgeraniol, Methods Mol. Biol. 116, 107–123.PubMedGoogle Scholar
  14. 14.
    Crick, D.C., Andres, D.A., and Waechter, C.J. (1997) Novel Salvage Pathway Utilizing Farnesol and Geranylgeraniol for Protein Isoprenylation, Biochem. Biophys. Res. Commun. 237, 483–487.PubMedCrossRefGoogle Scholar
  15. 15.
    Bentinger, M., Grünler, J., Peterson, E., Swiezewska, E., and Dallner, G. (1998) Phosphorylation of Farnesol in Rat Liver Microsomes: Properties of Farnesol Kinase and Farnesyl Phosphate Kinase, Arch. Biochem. Biophys. 353, 191–198.PubMedCrossRefGoogle Scholar
  16. 16.
    Westfall, D., Aboushadi, N., Shackelford, J.E., and Krisans, S.K. (1997) Metabolism of Farnesol: Phosphorylation of Farnesol by Rat Liver Microsomes and Peroxisomal Fractions, Biochem. Biophys. Res. Commun. 230, 562–568.PubMedCrossRefGoogle Scholar
  17. 17.
    Bassa, B.V., Roh, D.D., Vaxiri, N.D., Kirschenbaum, M.A., and Kamanna, V.S. (1999) Effects of Inhibition of Cholesterol Synthetic Pathway on the Activation of Ras and MAP Kinase in Mesanglial Cells, Biochim. Biophys. Acta 1449, 137–149.PubMedCrossRefGoogle Scholar
  18. 18.
    Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951) Protein Measurement with the Folin Phenol Reagent, J. Biol. Chem. 193, 265–275.PubMedGoogle Scholar
  19. 19.
    Ciosek, C.P., Magnin, D.R., Harrity, T.W., Logan, J.V., Dickson, J.K., Gordon, E.M., Hamilton, K.A., Jolibois, K.G., Kunselman, L.K., Lawrence, R.M., et al. (1993) Lipophilic 1,1-Bisphosphanates Are Potent Squalene Synthase Inhibitors and Orally Active Cholesterol Lowering Agents in vivo, J. Biol. Chem. 268, 24832–24837.PubMedGoogle Scholar
  20. 20.
    Yachnin, S., Golomb, H.M., West, E.J., and Saffold, C. (1983) Increased Cholesterol Biosynthesis in Leukemic Cells from Patients with Hairy Cell Leukemia, Blood 61, 50–60.PubMedGoogle Scholar
  21. 21.
    Ott, R.L. (1993) An Introduction to Statistical Methods and Data Analysis, 4th edn., Duxbury Press, Belmont, California.Google Scholar
  22. 22.
    Hohl, R.J., and Lewis, K. (1995) Differential Effects of Monoterpenes and Lovastatin on RAS Processing, J. Biol. Chem. 29, 17508–17512.Google Scholar
  23. 23.
    Vogt, A., Qian, Y., McGuire, T.F., Hamilton, A.D., and Sebti, S.M. (1996) Protein Geranylgeranylation, Not Farnesylation, Is Required for the G1 to S Phase Transition in Mouse Fibroblasts, Oncogene 13, 1991–1999.PubMedGoogle Scholar
  24. 24.
    McGuire, T.F., Qian, Y., Vogt, A., Hamilton, A.D., and Sebti, S.M. (1996) Platelet-Derived Growth Factor Receptor Tyrosine Kinase Phosphorylation Requires Protein Geranylgeranylation but Not Farnesylation, J. Biol. Chem. 44, 27402–27407.Google Scholar
  25. 25.
    McGuire, T.F., and Sebti, S.M. (1997) Geranylgeraniol Potentiates Lovastatin Inhibition of Oncogenic H-Ras Processing and Signaling While Preventing Cytotoxicity, Oncogene 14, 305–312.PubMedCrossRefGoogle Scholar
  26. 26.
    Koch, G., Benz, C., Schmidt, G., Olenik, C., and Aktories, K. (1997) Role of Rho Protein in Lovastatin-Induced Breakdown of Actin Cytoskeleton, J. Pharmacol. Exp. Ther. 283, 901–909.PubMedGoogle Scholar
  27. 27.
    Bradfute, D.L., and Simoni, R.D. (1994) Non-Sterol Compounds That Regulate Cholesterolgenesis, J. Biol. Chem. 269, 6645–6650.PubMedGoogle Scholar
  28. 28.
    Correll, C.C., Ng, L., and Edwards, P.A. (1994) Identification of Farnesol as the Non-sterol Derivative of Mevalonic Acid Required for the Accelerated Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase, J. Biol. Chem. 269, 17390–17393.PubMedGoogle Scholar
  29. 29.
    Meigs, T.E., Roseman, D.S., and Simoni, R.D. (1996) Regulation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Degradation by the Nonsterol Mevalonate Metabolite Farnesol in Vivo, J. Biol. Chem. 271, 7916–7922.PubMedCrossRefGoogle Scholar
  30. 30.
    Meigs, T.E., and Simoni, R.D. (1997) Farnesol as a Regulator of HMG-CoA Reductase Degradation: Characterization and Role of Farnesyl Pyrophosphatase, Arch. Biochem. Biophys. 345, 1–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Fliesler, S.J., and Keller, R.K. (1995) Metabolism of [3H]Farnesol to Cholesterol and Cholesterogenic Intermediates in the Living Rat Eye, Biochem. Biophys. Res. Commun. 21, 695–702.CrossRefGoogle Scholar
  32. 32.
    Dorsey, J.K., and Porter, J.W. (1968) The Inhibition of Mevalonic Kinase by Geranyl and Farnesyl Pyrophosphates, J. Biol. Chem. 243, 4667–4670.PubMedGoogle Scholar
  33. 33.
    Leonard, S., Beck, L., and Sinensky, M. (1990) Inhibition of Isoprenoid Biosynthesis and the Post-translational Modification of pro-p21ras, J. Biol. Chem. 9, 5157–5160.Google Scholar
  34. 34.
    Bansal, V.S., and Vaidya, S. (1994) Characterization of Two Distinct Allyl Pyrophosphatase Activities from Rat Liver Microsomes, Arch. Biochem. Biophys. 315, 393–399.PubMedCrossRefGoogle Scholar
  35. 35.
    Haug, J.S., Goldner, C.M., Yazlovitskaya, E.M., Voziyan, P.A., and Melnykovych, G. (1994) Directed Cell Killing (apoptosis) in Human Lymphoblastoid Cells Incubated in the Presence of Farnesol: Effect of Phosphatidylcholine, Biochim. Biophys. Acta 1223, 133–140.PubMedCrossRefGoogle Scholar
  36. 36.
    Ohizumi, H., Masuda, Y., Nakajo, S., Sakai, I., Ohsawa, S., and Nakaya, K. (1995) Geranylgeraniol Is a Potent Inducer of Apoptosis in Tumor Cells, J. Biochem. 117, 11–13.PubMedGoogle Scholar

Copyright information

© AOCS Press 2001

Authors and Affiliations

  1. 1.Department of Pharmacology, College of MedicineUniversity of IowaIowa City

Personalised recommendations